We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Monkeypox, a viral zoonotic disease caused by the monkeypox virus (MPXV), has gained global attention due to its outbreaks and implications for public health. As with many viral infections, the need for specific diagnostic tools, vaccines, and treatments is critical to manage the spread of the disease. One of the critical components in developing such solutions lies in the identification and development of specific antibodies, such as those targeting the Viral Glycoprotein (VGF). Creative Biolabs provides comprehensive monkeypox VGF antibody development services, offering cutting-edge solutions for researchers and institutions involved in monkeypox research and drug development.
VGF plays an essential role in the viral life cycle, particularly in mediating viral entry into host cells. In monkeypox, the VGF facilitates the virus's ability to infect host cells by binding to cell surface receptors, allowing viral fusion and subsequent replication. The VGF is an essential target for immune responses, making it a critical biomarker for antibody development. Creative Biolabs offers specialized services to develop antibodies targeting this crucial viral component.
Creative Biolabs provides a comprehensive suite of VGF-specific antibody development services to aid in the research and application of anti-monkeypox therapies and diagnostics. These services focus on generating high-affinity antibodies that specifically bind to the VGF of the monkeypox virus, ensuring that researchers have access to tools that can reliably detect or neutralize the virus. Our monkeypox VGF antibody development process includes:
We start by designing and optimizing the VGF immunogen to elicit a strong and specific immune response. This is followed by recombinant expression of VGF or its relevant fragments, ensuring the immunogen is properly folded and functional.
Using advanced techniques such as hybridoma technology, phage display, and transgenic animal models, we generate monoclonal and polyclonal antibodies that bind specifically to VGF. Our platforms allow for the generation of high-affinity antibodies with exceptional specificity.
To enhance the affinity and specificity of the antibodies, we employ affinity maturation techniques such as in vitro evolution or directed evolution, ensuring that the antibodies exhibit optimal performance in diagnostic assays or neutralization studies.
After generating the antibodies, they undergo rigorous testing to evaluate their binding efficiency, specificity, and neutralizing ability. This includes enzyme-linked immunosorbent assays (ELISA), western blotting, immunohistochemistry (IHC), and neutralization assays to confirm their functionality.
For applications requiring large quantities of antibodies, we offer scalable production services, including mammalian cell culture-based production or bacterial expression systems, ensuring that high-quality antibodies are available in large volumes for commercial or research use.
The VGF in monkeypox is a critical protein for viral entry and fusion. During infection, MPXV binds to host cells via receptors on the cell membrane, facilitated by the interaction between the VGF and host cell surface molecules. This binding triggers fusion between the viral envelope and the host cell membrane, allowing the virus to release its genetic material into the host cell and initiate replication.
VGF also plays a role in modulating immune responses. It can impact the host immune system’s ability to recognize and eliminate infected cells. By producing antibodies against VGF, researchers can potentially neutralize the virus, preventing it from entering host cells and reducing the overall viral load in infected tissues.
| Cat# | Product Name | Target | Antibody Isotype | Species Reactivity | Applications |
|---|---|---|---|---|---|
| MPYF-0922-KX1260 | Anti-Cowpox virus VGF Monoclonal Antibody (MP-K395) (Mouse IgG) | VGF | Mouse IgG | Cowpox virus | WB (Other applications need to be tested) |
| Cat# | Product Name | Species | Expression System | Target Protein | Protein Length |
|---|---|---|---|---|---|
| MPYF-0722-KX689 | Magic™ Cowpox virus (Brighton Red) VGF Recombinant Protein | Cowpox virus | Based on specific requirements | VGF | Full length |
Creative Biolabs utilizes a range of advanced platforms and technologies in the development of VGF antibodies:
A powerful method to screen for high-affinity antibodies by displaying antibody fragments on the surface of phages.
A traditional and reliable method for producing monoclonal antibodies against viral targets.
We use genetically modified animals to generate polyclonal antibodies that closely mimic human immune responses.
Ensuring that antibodies are not only effective in laboratory settings but also functional in relevant biological models.
The antibodies targeting VGF have various potential applications:
Creative Biolabs stands out as a leader in the field of antibody development for infectious diseases like monkeypox. Our VGF antibody development services offer several distinct advantages:
VGF antibodies are developed through several methods, including hybridoma technology, phage display, and the use of transgenic animal models to generate both monoclonal and polyclonal antibodies that specifically bind to the VGF.
Yes, Creative Biolabs offers scalable antibody production services, using both mammalian and bacterial expression systems to meet the needs of your research or commercial requirements.
While the antibodies developed for monkeypox VGF are tailored to this specific virus, they may also cross-react with other orthopoxviruses, depending on the degree of similarity in the glycoprotein structure. However, for definitive applications against other viruses, additional testing and optimization may be required.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.